Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | TNKS | O95271 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 3/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.30 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869386 | 0.84 | CTSS (0.35) | SMN1; SMN2ALDH1A1LMNATP53RAB9A | |
| SCHEMBL3873933 | 0.84 | SMYD3 (0.36) | CNR2ALDH1A1LMNAALOX15RAB9A | |
| SCHEMBL3871936 | 0.84 | CNR2 (0.33) | CNR2ALDH1A1RAB9A | |
| SCHEMBL3870461 | 0.79 | MMP1 (0.40) | ALDH1A1RAB9AHDAC3HDAC1HDAC6 | |
| SCHEMBL3870483 | 0.77 | PDK1 (0.30) | — | |
| SCHEMBL3871979 | 0.75 | FAAH (0.45) | RAB9AMEN1KMT2ACTSSCTSK | |
| SCHEMBL3870025 | 0.75 | PDK1 (0.33) | MEN1KMT2ACTSK | |
| SCHEMBL3872609 | 0.75 | LIPG (0.35) | LIPGSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL8290655 | 0.68 | CTSS (0.45) | CTSSCTSK | |
| SCHEMBL5393841 | 0.66 | CTSS (0.35) | SMN1; SMN2ALDH1A1KDM4ELMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | LIPG 313/4885TNKS 497/4885CNR2 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.